Bazedoxifene (Wyeth).

Article Details

Citation

Gruber C, Gruber D

Bazedoxifene (Wyeth).

Curr Opin Investig Drugs. 2004 Oct;5(10):1086-93.

PubMed ID
15535430 [ View in PubMed
]
Abstract

Bazedoxifene is a tissue-specific selective estrogen receptor modulator being developed by Wyeth Pharmaceuticals (formerly Wyeth-Ayerst Laboratories) to be used alone for the prevention and treatment of osteoporosis in postmenopausal women and in combination with Premarin for menopausal symptoms. As of March and June 2004, worldwide phase III trials for bazedoxifene, and bazedoxifene in combination with Premarin, were ongoing.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
BazedoxifeneEstrogen receptor alphaProteinHumans
Yes
Antagonist
Agonist
Details